Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Learn when mutual funds can be preferable to index funds, considering objectives, risk tolerance, and horizon. Make informed allocation decisions.
25,127 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A record M&A surge, pegged at roughly $4 trillion for 2026, is shaping the market. Wall Street is weighing whether a ...
Telecom stocks face a yield squeeze as SpaceX's Starlink tests the bounds of traditional connectivity. This report we...
In June, gold and silver prices pulled back, pressuring Hycroft Mining, a Nevada-focused, single-mine precious metals...
Intel’s stock whipsawed after a dramatic breakout, triggering a deeper look at whether the move can sustain amid AI d...
New Hampshire's Executive Council rejected a proposed $100 million Bitcoin-backed municipal bond in a 3-2 vote, halti...
Ethereum outperformed XRP in July as new institutional money flowed back into ETH. Traders debate which crypto offers...
Bitcoin has pulled back sharply from recent highs, leaving both new and seasoned investors wondering what comes next....
Thinking Machines launches Inkling, its inaugural broad-use AI model. The move highlights a shift toward accessible A...
Investors chasing SpaceX-style wins without a private bet must weigh public players carefully. This guide compares AS...
A high-profile lawsuit highlights how quickly legal exposure can strain a creator’s finances. Learn practical steps t...
A growing cohort of self-custody Bitcoin holders now rides a steep unrealized-loss trail, while ETFs trimming exposur...